Nectar Lifesciences Limited has informed the Exchange about updation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences Limited's board, at a meeting held on March 02, 2026, approved infusing up to INR 120 crores as an inter-corporate loan to its proposed wholly owned subsidiary, Avensis Exports Private Limited. The loan will be provided after completion of the acquisition of Avensis. This disclosure is a continuation and forms part of the company's earlier letter dated March 02, 2026. Detailed disclosures on the loan agreement will be shared with the stock exchanges later as per the SEBI Master Circular dated January 30, 2026. The company also acknowledged that the delay in sharing these details was due to an administrative oversight and assured timely disclosures in the future.
The INR 120 crore loan represents a significant capital deployment by Nectar Lifesciences into a new wholly owned subsidiary, which may affect the company's cash position and liquidity in the short term. Shareholders should watch for further details on the acquisition of Avensis Exports and the terms of the loan, as this could be material to the company's growth strategy and future financial statements.